BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 08-Oct-2017

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 16, 2017 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.

SQURPHARMA 20-Aug-2017

The Company has informed that a total of 2,62,47,368 shares of late Sponsor Dr. Kazi Harunar Rashid has been transmitted to his legal heirs according to the succession certificate issued by the Honorable Court: i) 1,31,23,684 shares to Mr. Kazi Iqbal Harun (son, Director of the Company), ii) 65,61,842 shares to Mrs. Nilufar Ferdous (daughter) and iii) 65,61,842 shares to Mrs. Nargis Ferdous (daughter).

SQURPHARMA 11-Jun-2017

The Company has informed that the Board of Directors has approved agreements with M/s. NAAFCO Pharma Ltd. and M/s. Sharif Pharmaceuticals Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals Limited to meet increased demand of existing products and to introduce new products.

SQURPHARMA 02-May-2017

(Q3 Un-audited): Consolidated EPS was Tk. 4.27 for January-March 2017 as against Tk. 3.64 for January-March 2016; Consolidated EPS was Tk. 11.39 for July 2016-March 2017 as against Tk. 9.74 for July'15-March'16. Consolidated NOCFPS was Tk. 12.35 for July 2016-March 2017 as against Tk. 12.08 for July 2015-March 2016. Consolidated NAV per share was Tk. 67.51 as of March 31, 2017 and Tk. 59.13 as of June 30, 2016.

SQURPHARMA 25-Apr-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.

SQURPHARMA 29-Jan-2017

(Q2 Un-audited): Consolidated EPS was Tk. 3.58 for October-December, 2016 as against Tk. 3.21 for October-December, 2015; Consolidated EPS was Tk. 7.11 for July-December, 2016 as against Tk. 6.10 for July-December, 2015. Consolidated NOCFPS was Tk. 8.54 for July-December, 2016 as against Tk. 8.93 for July-December, 2015. Consolidated NAV per share was Tk. 63.00 as of December 31, 2016 and Tk. 59.13 as of June 30, 2016.

SQURPHARMA 23-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

SQURPHARMA 17-Jan-2017

The Company has informed that it has disbursed the cash dividend warrants for the 15 months period ended on June 30, 2016 to the respective shareholders' mailing address.

SQURPHARMA 09-Jan-2017

The Company has informed that the Board of Directors has decided to establish a pharmaceuticals manufacturing subsidiary company in Nairobi, Kenya. The Initial estimated total project cost will be US$ 20.00 million. US$ 8.00 million of it will be financed by equity investment by the company for which Bangladesh Bank has given permission and the balance would be invested from loan. It is expected that the project would be completed by June 2019.

SQURPHARMA 27-Dec-2016

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2016, unaudited financials up to September 30, 2016 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

Previous Next page